ABL1 and acute lymphoblastic leukemia: To further study the consequences of ruxolitinib on leukemia cells in vivo, we injected human BCR-ABL+ ALL cells into NSG mice and monitored the recipient mice under imatinib, ruxolitinib, or combined imatinib/ruxolitinib treatment.